drugset

drugset / Trial / NCT04397263

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT04397263 ↗

Phase 3 Completed 38 enrolled Janssen Pharmaceutical K.K.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.

Timeline

Start: 2020-06-10
Primary completion: 2024-02-29
Completion: 2025-09-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Guselkumab	Monoclonal antibody	—	Intravenous

Indications